Ovarian Metastasis of ALK Translocation-Positive Lung Adenocarcinoma: A Case Report

Creative Commons License

Gezer S., ÇABUK D., AKSOY L., Ozturk S., Ozkara S., YÜCESOY İ.

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, cilt.35, sa.4, ss.475-478, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 35 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5505/tjo.2020.2214
  • Dergi Adı: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.475-478
  • Kocaeli Üniversitesi Adresli: Evet

Özet

Ovarian metastasis is substantially rare in non-small cell lung cancer (N-SCLC). Driver gene mutations, such as Anaplastic Lymphoma Kinase (ALK), are used in the diagnosis of N-SCLC and its metastases. Demonstration of ALK mutation in N-SCLC patients will be helpful for detecting ovarian metastasis and planning personalized therapy; however, there is a limited number of cases related to this topic. In this case, we present the diagnosis and treatment of ALK-positive non-small cell lung adenocarcinoma patient with ovarian metastasis. Crizotinib is the first-class tyrosine kinase inhibitor using for the treatment of ALK-positive N-SCLC. The ovarian metastasis has been treated with surgery while under Crizotinib treatment. The patient continues to receive crizotinib treatment and no new metastases were detected at the end of a one-year follow-up. The possibility of ovarian metastasis in female N-SCLC patients with ALK rearrangement should be kept in mind.